JP5474547B2 - Ｈｃｖ融合ポリペプチド - Google Patents

Ｈｃｖ融合ポリペプチド Download PDF

Info

Publication number
JP5474547B2
JP5474547B2 JP2009525662A JP2009525662A JP5474547B2 JP 5474547 B2 JP5474547 B2 JP 5474547B2 JP 2009525662 A JP2009525662 A JP 2009525662A JP 2009525662 A JP2009525662 A JP 2009525662A JP 5474547 B2 JP5474547 B2 JP 5474547B2
Authority
JP
Japan
Prior art keywords
amino acids
hcv
sequence
core
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009525662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501580A (ja
JP2010501580A5 (enExample
Inventor
マイケル ホートン，
イン−リン リン，
アンジェリカ メディナ−セルビー，
ドリス コイト，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010501580A publication Critical patent/JP2010501580A/ja
Publication of JP2010501580A5 publication Critical patent/JP2010501580A5/ja
Application granted granted Critical
Publication of JP5474547B2 publication Critical patent/JP5474547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009525662A 2006-08-25 2007-08-27 Ｈｃｖ融合ポリペプチド Active JP5474547B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84016206P 2006-08-25 2006-08-25
US60/840,162 2006-08-25
PCT/US2007/018940 WO2008024518A2 (en) 2006-08-25 2007-08-27 Hcv fusion polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013241514A Division JP2014036675A (ja) 2006-08-25 2013-11-22 Ｈｃｖ融合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2010501580A JP2010501580A (ja) 2010-01-21
JP2010501580A5 JP2010501580A5 (enExample) 2010-11-11
JP5474547B2 true JP5474547B2 (ja) 2014-04-16

Family

ID=38969483

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009525662A Active JP5474547B2 (ja) 2006-08-25 2007-08-27 Ｈｃｖ融合ポリペプチド
JP2013241514A Withdrawn JP2014036675A (ja) 2006-08-25 2013-11-22 Ｈｃｖ融合ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013241514A Withdrawn JP2014036675A (ja) 2006-08-25 2013-11-22 Ｈｃｖ融合ポリペプチド

Country Status (5)

Country Link
US (1) US8216590B2 (enExample)
EP (1) EP2061888A2 (enExample)
JP (2) JP5474547B2 (enExample)
CA (1) CA2661492A1 (enExample)
WO (1) WO2008024518A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163558A1 (en) * 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
WO2018055535A2 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
BR102018071672A2 (pt) * 2018-10-22 2021-11-16 Fundação Oswaldo Cruz Polipeptídeo, cassete de expressão, vetor de expressão, célula hospedeira, kit para triagem imunológica de hcv e/ou diagnóstico de hepatite c, composição, uso de pelo menos um polipeptídeo, e, métodos para produzir um polipeptídeo, para triagem imunológica de hcv e para o diagnóstico de hepatite c

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
ES2188583T3 (es) 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
UA39944C2 (uk) 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
US6054424A (en) 1998-04-15 2000-04-25 Church & Dwight Co., Inc. Process for the production of a liquid laundry detergent composition of desired viscosity containing nonionic and anionic surfactants
ES2281179T3 (es) 1998-06-09 2007-09-16 Andrea D. Branch Nuevos peptidos del virus de la hepatitis c y usos de los mismos.
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
EP1233982B1 (en) * 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Novel hcv non-structural polypeptide
CA2491508A1 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains
WO2004039950A2 (en) 2002-10-25 2004-05-13 Chiron Corporation Activation of hcv-specific cells
RU2006144714A (ru) * 2004-05-17 2008-06-27 Чирон Корпорейшн (Us) Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки
ES2377978T3 (es) * 2004-08-27 2012-04-03 Novartis Vaccines And Diagnostics, Inc. Mutantes de proteínas no estructurales de VHC y usos de los mismos

Also Published As

Publication number Publication date
WO2008024518A3 (en) 2008-04-10
JP2014036675A (ja) 2014-02-27
US8216590B2 (en) 2012-07-10
JP2010501580A (ja) 2010-01-21
WO2008024518A2 (en) 2008-02-28
US20100092503A1 (en) 2010-04-15
EP2061888A2 (en) 2009-05-27
CA2661492A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
US20090098153A1 (en) Activation of HCV-specific T cells
US20100291134A1 (en) Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
JP2006265267A (ja) 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質
US7439058B2 (en) HBV/HCV virus-like particle
JP4647870B2 (ja) Ｈｂｖ／ｈｃｖウイルス様粒子
JP5405832B2 (ja) Ｈｃｖ特異的なｔ細胞の活性化
JP5474547B2 (ja) Ｈｃｖ融合ポリペプチド
US20050074465A1 (en) HCV fusion proteins with modified NS3 domains
CA2505611A1 (en) Activation of hcv-specific cells
EP1535628B1 (en) Hbv/hcv virus-like particle

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131122

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140205

R150 Certificate of patent or registration of utility model

Ref document number: 5474547

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250